Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04777162
Status:
UNKNOWN
Last Update Posted:
2021-03-04
First Post:
2021-02-25
Brief Title:
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Sponsor:
Peking University
Organization:
Peking University
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-05
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-25
First Submit QC Date:
February 26 2021
Study First Post Date:
2021-03-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-03-02
Last Update Post Date:
2021-03-04
Last Update Post Date Type:
ACTUAL